Werewolf Therapeutics Inc (HOWL)

05:12 AM

Werewolf Therapeutics Inc. stock trendline breakdownRate Hike & Fast Entry Momentum Trade Alerts - newser.com

05:12 AM

05:11 AM

Predicting Werewolf Therapeutics Inc. trend using moving averagesSwing Trade & Reliable Volume Spike Alerts - newser.com

05:11 AM

Oct 13, 2025

Identifying reversal signals in Werewolf Therapeutics Inc.Market Performance Report & Capital Protection Trading Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

How to recover losses in Werewolf Therapeutics Inc. stockJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com

Oct 13, 2025

Oct 13, 2025

Analyzing recovery setups for Werewolf Therapeutics Inc. investorsJuly 2025 News Drivers & AI Based Buy/Sell Signal Reports - newser.com

Oct 13, 2025

Oct 10, 2025

Will Werewolf Therapeutics Inc. stock maintain dividend yieldQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

Using data tools to time your Werewolf Therapeutics Inc. exit2025 Top Gainers & Fast Entry Momentum Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Weiss Ratings Reaffirms "Sell (D-)" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat

Oct 09, 2025

Oct 09, 2025

How high can Werewolf Therapeutics Inc. stock goEarnings Summary Report & Reliable Intraday Trade Alerts - newser.com

Oct 09, 2025

Oct 08, 2025

Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Nigeria

Oct 08, 2025

Oct 08, 2025

Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener

Oct 08, 2025

Oct 08, 2025

Werewolf Therapeutics receives FDA Fast Track for melanoma therapy - Investing.com

Oct 08, 2025

Oct 08, 2025

Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener

Oct 08, 2025

Oct 08, 2025

Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire

Oct 08, 2025

Oct 08, 2025

Fast Track for WTX-124: Werewolf advances IL-2 INDUKINE for relapsed cutaneous melanoma - Stock Titan

Oct 08, 2025

Oct 06, 2025

Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks

Oct 06, 2025

Oct 06, 2025

Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com

Oct 06, 2025

Oct 06, 2025

Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com

Oct 06, 2025

Oct 06, 2025

Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com

Oct 06, 2025

Oct 05, 2025

Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com

Oct 05, 2025

Oct 05, 2025

Intraday pattern recognizer results for Werewolf Therapeutics Inc.Fed Meeting & Weekly High Return Stock Forecasts - newser.com

Oct 05, 2025

Oct 04, 2025

Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛

Oct 04, 2025

Oct 03, 2025

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire

Oct 03, 2025

Oct 03, 2025

Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative

Oct 03, 2025

Oct 03, 2025

3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan

Oct 03, 2025

Sep 30, 2025

Published on: 2025-09-30 05:19:05 - newser.com

Sep 30, 2025

Sep 30, 2025

Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World

Sep 30, 2025

Sep 30, 2025

Published on: 2025-09-30 01:50:53 - newser.com

Sep 30, 2025